{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:19:53Z","timestamp":1787170793116,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006209","name":"N.P.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013119","name":"PharmaMar","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013119","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006413","name":"Ariad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BMS"},{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"INCa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"INCa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ejca.2019.12.001","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T23:14:06Z","timestamp":1578352446000},"page":"45-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib"],"prefix":"10.1016","volume":"126","author":[{"given":"Nicolas","family":"Penel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Le Cesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Delcambre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Bompas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Bertucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esma","family":"Saada-Bouzid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Chaigneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chevreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brodowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Decoupigny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Vanseymortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-C\u00e9cile","family":"Le Deley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.12.001_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020294","article-title":"Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing","volume":"6","author":"Ducimeti\u00e8re","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2019.12.001_bib2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/cncr.31176","article-title":"Presentation and outcome of frequent and rare sarcoma histologic subtypes: a study of 10,262 patients with localized visceral\/soft tissue sarcoma managed in reference centers","volume":"124","author":"Penel","year":"2018","journal-title":"Cancer"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2019.12.001_bib3","doi-asserted-by":"crossref","first-page":"iv51","DOI":"10.1093\/annonc\/mdy096","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.12.001_bib4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJMra041866","article-title":"Soft-tissue sarcomas in adults","volume":"353","author":"Clark","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.12.001_bib5","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf WT1","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2019.12.001_bib6","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.12.001_bib7","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in prviously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised open label, multicenter, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2019.12.001_bib8","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/cncr.25538","article-title":"Trends in survival for patients with metastatic soft-tissue sarcoma","volume":"117","author":"Italiano","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2019.12.001_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40425-017-0301-y","article-title":"Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials","volume":"5","author":"Groisberg","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2019.12.001_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","article-title":"Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial","volume":"4","author":"Toulmonde","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2019.12.001_bib11","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1002\/cncr.29426","volume":"121","author":"Coens","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2019.12.001_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2018.05.008","article-title":"Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma","volume":"99","author":"Brodowicz","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.12.001_bib13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.12.001_bib14","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3","article-title":"Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group","volume":"91","author":"Coindre","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2019.12.001_bib15","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(16)30507-1","article-title":"Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.12.001_bib16","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2019.12.001_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40259-013-0014-9","article-title":"Regorafenib for gastrointestinal malignancies: from preclinical data to clinical results of a novel multi-target inhibitor","volume":"27","author":"Aprile","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejca.2019.12.001_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2019.04.030","article-title":"Olaratumab failure in sarcomas: what are the lessons learned?","volume":"117","author":"Italiano","year":"2019","journal-title":"Eur J Cancer"},{"issue":"10043","key":"10.1016\/j.ejca.2019.12.001_bib19","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0140-6736(16)30587-6","article-title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","volume":"388","author":"Tap","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2019.12.001_bib20","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.2010.33.6107","article-title":"Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish group for research on sarcomas study","volume":"29","author":"Garc\u00eda-del-Muro","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.12.001_bib21","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised generic, validated approach to stratify the magnitude of the clinical benefit that can anticipated from ati-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Chernyl","year":"2015","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919308524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919308524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:26:03Z","timestamp":1760732763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919308524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":21,"alternative-id":["S0959804919308524"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.12.001","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}